Claudine Isaacs, MD
Provider accepts MedStar Select insurance

4.9 out of 5 (222 reviews)

Specialities: Cancer Genetics, Breast Medical Oncology

Languages: English

202-444-9429

About me

Dr. Claudine Isaacs is a medical oncologist who specializes in the care of women with all stages of breast cancer. She is Professor of Medicine and Oncology, Associate Director of Clinical Research and Leader of the Clinical Breast Cancer Program at the Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University. She is also the Medical Director of the Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research. She has been practicing for over 20 years.

Dr. Isaacs received her medical degree and internal medicine residency training at McGill University, Canada. She completed fellowship training in the Division of Hematology and Oncology at McGill University and a Fellowship in Breast Medical Oncology in the Division of Medical Oncology at Georgetown University. She then joined the faculty in the Department of Medicine and Oncology at Georgetown University.

Dr. Isaacs has extensive experience in the conduct of clinical trials focusing on all aspects of breast cancer. Additional research interests include cancer risk assessment and medical management and prevention strategies for women at high risk for breast cancer. She has served as the principal investigator of a variety of clinical trials in the treatment of early-stage and metastatic breast cancer, and currently serves as the principal investigator of the Translational Breast Cancer Research Consortium (TBCRC), the ISPY2 trial at Georgetown University. She has authored over 200 peer reviewed publications. She has also served on a number of committees, including the Cancer Education Committee at the American Society of Clinical Oncology (ASCO), the ASCO Scientific Program Committee, the Breast Oncology Local Diseases Task Force of the Breast Steering Committee of the National Cancer Institute, and most recently the ASCO guidelines committee. She has been named one of America's Top Cancer Doctors by Castle Connolly/Newsweek for many years running, and has also received designations from Washingtonian Magazine and Women's Health Magazine.


Dr. Isaacs' Philosophy of Care:

I strive to personalize the care of my patients by tailoring state-of-the-art therapy to their individual situations and by providing them with access to cutting-edge clinical trials. Equally important is that the care of my patients extends well beyond focusing just on the optimal therapy of their cancer.  My approach to care is to relate to each of my patients as individuals in the context of their lives, and not solely based on the characteristics of their disease. To that end, I work with a wonderful and dedicated multidisciplinary group of expert colleagues who are deeply committed to and involved with our patients' care. The whole team is focused solely on breast cancer and includes medical oncologists, surgeons, radiation oncologists, breast imagers and pathologists who are supported by an experienced team of clinical nurse coordinators, nurse navigators, research nurses, genetic counselors and social workers, all championing a multidisciplinary approach to breast cancer diagnosis, treatment and recovery. We are not treating a disease. We are treating a person and we are here to provide state-of-the-art medical treatment and to accompany that person navigates their cancer journey.

Conditions and procedures

Conditions I treat

  • Brca
  • Breast Cancer
  • Breast Cancer During Pregnancy
  • Breast Cancer In Young Women
  • Carcinoma In Situ Of Breast
  • Ductal Carcinoma In Situ Dcis
  • Er Positive Breast Cancer
  • Family History Of Breast Cancer
  • Her2neu Receptor
  • Hereditary Breast And Ovarian Cancer
  • Inflammatory Breast Cancer
  • Invasive Breast Cancer
  • Lobular Carcinoma In Situ Lcis
  • Male Breast Cancer
  • Metastatic Axillary Cancer
  • Metastatic Breast Cancer
  • Recurrent Breast Cancer
  • Treatment Refractory Breast Cancer
  • Triple Negative Breast Cancer
Show All Show Less

Procedures I perform

  • Breast Cancer Biological Targeted Therapy
  • Breast Cancer Chemotherapy
  • Breast Cancer Follow Up
  • Breast Cancer Genetics
  • Cancer Immunotherapy
  • Chemoradiation
  • High Risk Breast Cancer Counseling
  • Neoadjuvant Chemotherapy
Show All button Press enter to expand Show Less

Practice locations

Distance from Change LocationEnter your Location

3800 Reservoir Road Northwest
Lombardi Cancer Center
Washington, DC, 20007

202-444-2223

Fax 866-495-1112

Get Directions

miles away

Fax 866-495-1112

Insurance

MedStar Medical Group accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Medical Group, please call your insurance company.

  • List of insurance plans we accept
    • Aetna Elect Choice/ EPO (Aetna Health Fund) Innovation Health: Network Only Plus
    • Aetna Quality Point of Service (POS)
    • Aetna USAccess (POS)
    • Aetna Student Health Insurance
    • Aetna Medicare Advantage HMO & PPO Plans
    • CFBCBS BlueChoice HMO
    • CFBCBS Blue Choice Opt Out Plus Open Access (POS)
    • CFBCBS Maryland Point of Service Plan (MPOS)
    • CFBCBS Federal Employee Program (Std. & Basic PPO)
    • CFBCBS Maryland Indemnity or PPO
    • CFBCBS (NCA) Indemnity
    • CIGNA HMO & Network (HMO)
    • CIGNA POS/Network POS
    • Great-West Healthcare POS/CIGNA
    • CIGNA Indemnity
    • Coventry Health Care of Virginia
    • Coventry of Delaware HMO/PPO
    • First Health PPO
    • FIRST HEALTH
    • Tricare Prime
    • Tricare Standard
    • Tricare Extra (Indemnity)
    • Tricare for Life (Medicare Supplemental Plan)
    • MedStar Family Choice - Maryland Health Choice
    • MedStar Select (MedStar Associates' Plan)
    • MedStar Medicare Choice
    • United Healthcare Select HMO - EPO/NPP
    • United Healthcare Select Plus (POS)
    • United Healthcare Choice Plus
    • United Student Resources
    • M.D. IPA (HMO)
    • M.D. IPA Preferred (POS)
    • Optimum Choice Preferred (POS) & OCI Direct (HMO)
    • Mamsi Life & Health (Indem./PPO)
    • Aetna Worker's Compensation Network
    • Coventry Health Care National Network PPO
    • Private Health Care Systems (PHCS) (PPO)
    • United Healthcare Options (PPO) (includes Empire PPO, GEHA, Compass Rose)
    • OneNet PPO, Inc.
    • United Healthcare Choice
    • United Healthcare Core Essential (HMO)
    • Optimum Choice
    • United Healthcare Navigate
    • United Healthcare Compass (HMO)
    • CIGNA HMO Open Access (OA)
    • Network OA
    • POS OA & OA Plus
    • CIGNA EPO
    • PPO and PPO Plus
    • Choice Fund PPO
    • CFBSBC Blue Preferred PPO
    • HealthyBlue PPO
    • CFBCBS Blue Choice Opt Out Open Access
    • BlueChoice Open Access
    • Blue Choice Advantage & Healthy Blue (HMO, POS)
    • Aetna Traditional Choice (PPO)
    • Innovation Health: Indemnity
    • Aetna Open Choice (PPO)
    • Innovation Health: PPO
    • Aetna Managed Choice (POS)
    • Innovation Health: POS Plus
    • Aetna Elect Choice/ Open Access (POS)
    • Innovation Health: Open Network Only Plus
    • Aetna HMO-Open Access/Select OA/HealthFund/Health Network Option OA
    • Innovation Health: POS
    • Open HMO
    • Opoen HMO Option
    • Open EPO Plus
    • Aetna Managed Choice Open Access (POS)
    • Choice POS & Choice POS II
    • Innovation Health: Open POS Plus
    • Open POS II
    • Aetna HMO
    • Select HMO/HealthFund/Health Network
    • Aetna Innovations: HMO & EPO Plus

Videos

Education

Board Certification: American Board of Internal Medicine, Medical Oncology

Fellowship Program: MedStar Georgetown University Hospital (1993)

Fellowship Program: McGill University (1992)

Internship/Residency: Montreal General Hospital (1990)

Residency Program: McGill University (1990)

Internship Program: Montreal General Hospital (1988)

Medical School: McGill University (1987)

Awards

    • America’s Top Doctors for Women, Women’s Health Magazine
    • Marquis Who’s Who in America            
    • America’s Top Doctors, Castle Connolly
    • Newsweek’s Top Cancer Doctors
    • Top Doctors Washington DC, Washingtonian Magazine
    • Global Directory Top Doctors
    • Global Directory of Who’s Who
    • Top Doctors Washington DC Area, Northern Virginia Magazine
    • Estelle Ramey Mentorship Award, Georgetown University School of Medicine

News and publications

Select Publications:




  • Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM, Isaacs C. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27(31):5153-9. PMID 19752342

     

  • Schwartz M, Peshkin B, Hughes C, Main D, Isaacs C, Lerman C.  Impact of BRCA1/BRCA2 mutation testing on psychological distress in a clinic-based sample.  J Clin Oncol 2002;20:514-520.

     

  • Isaacs C, Peshkin BN, Schwartz M, DeMarco TA, Main D, Lerman C.  Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer.  Breast Cancer Res and Treat 2002;71:103-112.

     

  • Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, Bluemke DA, Bowen DJ, Marcom PK, Armstrong DK, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 2007;244(2):381-8.

     

  • Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer. 2011;118:510-517

     

  • Mandelblatt JS, Faul LA, Luta G, Makgoeng SB, Isaacs C, Taylor K, Sheppard VB, Tallarico M, Barry WT, Cohen HJ. Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901. J Clin Oncol 2012;(21):2609-14.

     

  • Sheppard VB, Isaacs C, Luta G.  Narrowing the racial gaps in breast cancer chemotherapy initiation: the role of the patient-provider relationship.   Breast Cancer Res Treat. 2013 May;139(1):207-16.

     

  • Potosky, A. L., O'Neill, S. C., Isaacs, C., Tsai, H.-T., Chao, C., Liu, C., Ekezue, B. F., Selvam, N., Kessler, L. G., Zhou, Y. and Schwartz, M. D.  Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years. Cancer. 2015;121(22):4062-70. 

     

  • Budd, G. T., Barlow, W. E., Moore, H. C., Hobday, T. J., Stewart, J. A., Isaacs, C., Salim M, Cho J, Rinn K, Albain K, Chew H, Burton G, Moore TD, Srkalovic G, McGregor B, Flaherty L, Livingston R, Lew D, Gralow J, Hortobagyi, G. N.   SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. J Clin Oncol, 2015;33(1), 58-64. PMID 25422488

     

  • Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer.   N Engl J Med. 2016 Jul 7;375(1):11-22. PMID: 27406346

     

  • Zhang X, Chiang HC, Wang Y, Zhang C, Smith S, Zhao X, Nair SJ, Michalek J, Jatoi I, Lautner M, Oliver B, Wang H, Petit A, Soler T, Brunet J, Mateo F, Angel Pujana M, Poggi E, Chaldekas K, Isaacs C, Peshkin BN, Ochoa O, Chedin F, Theoharis C, Sun LZ, Curiel TJ, Elledge R, Jin VX, Hu Y, Li R. Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. Nat Commun. 2017 Jun 26;8:15908. PMID: 28649985; PMCID: PMC5490191.

     

  • Mandelblatt JS, Small BJ, Luta G, Hurria A, Jim H, McDonald BC, Graham D, Zhou X, Clapp J, Zhai W, Breen E, Carroll JE, Denduluri N, Dilawari A, Extermann M, Isaacs C, Jacobsen PB, Kobayashi LC, Nudelman KH, Root J, Stern RA, Tometich D, Turner R, VanMeter JW, Saykin AJ, and Ahles T.  Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study.  J Clin Oncol 2018. DOI: 10.1200/JCO.18.00140.  PMID 30281396

     

  • Pohlmann PR, Isaacs C.  Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few. J Natl Cancer Inst. 2018 Jan 1;110(1). PMID: 28922782

     

  • Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, for CIMBA.  Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2018 Oct 12. doi: 10.1093/jnci/djy132. PMID: 30312457

     

  • Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.  JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00286. Epub 2018 Jul 23. PMID:30234181

     

  • Wood ME, Garber JE, Isaacs C, Masood S, Bedrosian I, Tung N, Chun J, Schnabel FR, Arun BK; International Society of Cancer Risk Assessment and Management. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast J. 2019 Jul;25(4):575-577. PMID: 31280501

     

  • Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien J, Forero-Tores A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, et al, for the I-SPY 2 Investigators.  Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.  JAMA Oncol. 2020;6(5):676-684

     

  • Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, et al for ISPY2. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1355-1362. PMID: 32701140; PMCID: PMC7378873.

     

  • Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020 Jun 20;38(18):2080-2106. PubMed PMID: 32243226.

     

  • Chandler Y, Jayasekera J, Schechter C, Isaacs C, Cadham C, Mandelblatt J. Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores. J Natl Cancer Inst. 2020 Jun 1;112(6):574-581.  PMID: 31612208

     

  • Ambrosone CB, Zirpoli GR, Hutson AD, McCann WE, McCann SE, Barlow WE, Kelly KM, Cannioto R, Sucheston-Campbell LE, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol. 2020 Mar 10;38(8):804-814. PMID: 31855498; PMCID: PMC7062457.

     

  • O'Neill SC, Taylor KL, Clapp J, Jayasekera J, Isaacs C, Mary Atieh Graham D, Goldberg SL, Mandelblatt J. Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives.J Health Commun. 2018;23(7):679-686. PMID:30130477

     

  • Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 Apr 1;38(10):1059-1069. PMID: 32031889; PMCID: PMC7106976.

     

  • Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 May 1;6(5):676-684. PMID: 32053137; PMCID: PMC7058271.

     

  • Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1410-1415. PMID: 32644110; PMCID: PMC7349081.



Complete List of Bibliography:  https://www.ncbi.nlm.nih.gov/myncbi/1JoY-eSaL0CAN/bibliography/public/


Ratings and reviews

  • Provider explained things understandably

    4.9
  • Provider listened carefully

    5.0
  • Provider gave easy to understand instructions

    4.9
  • Provider knew medical history

    4.9
  • Provider showed respect

    4.9
  • Provider spent enough time with patient

    4.9
  • Jul 20, 2021

    Claudine Isaacs is superb in every aspect of medical care, patient concern and current knowledge about her specialty. She is tops.

  • Jun 1, 2021

    Dr. Isaacs is the best.

  • May 4, 2021

    Dr. Isaacs is THE BEST! She is SO thorough in her thinking and implementation of my care. It is tremendously reassuring. I feel like I am getting the BEST of care.